Mentor Capital Cancer Immunotherapy Index Gains 29% During First Half of 2012

Mentor Capital Cancer Immunotherapy Index Gains 29% During First Half of 2012

Mentor Capital, Inc.Chester Billingsley, CEO760-788-4700

Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 28.7% during the first half of 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 30.7% gain. In comparison, during the first six months of 2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.42%, 8.31% and 12.66%, respectively.

Immunocellular Therapeutics (176%), Agenus (162%) and Celldex (99%) have led the sector in gains during the January thru June 2012 period. Cancer immunotherapy pioneer, Dendreon, dominates the market capitalization of the sector, representing 49% of the combined Cancer Immunotherapy Index total share value of $2.3 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their reported first half 2012 gains follow: Dendreon (NASDAQ:DNDN) -2.63%, Immunocellular Therapeutics, Ltd. (AMEX:IMUC) +175.74%, Agenus (NASDAQ:AGEN) +162.00%, Oncothyreon (NASDAQ:ONTY) -38.26%, Biovest International (BVTI.PK) +9.33%, Celldex Therapeutics (NASDAQ:CLDX) +99.04%, Northwest Biotherapeutics (OTCBB:NWBO) -36.46%, CEL – SCI Corp. (AMEX:CVM) +31.08% , Generex Biotechnology (OTCBB:GNBT) -38.67% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) +3.70% and Advaxis, Inc. (OTCBB:ADXS) -42.02% - all for an average six month gain of +28.72% (approximately +57.44% if annualized).

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies and those associated companies that reduce the cost of medical treatments. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index. The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.